Non-clear cell (ncc) metastatic renal-cell carcinoma (RCC) has dismal results with standard systemic therapies and a generally worse prognosis when compared to its clear-cell counterpart. New systemic combination therapies have emerged for metastatic RCC (mRCC), but the pivotal phase III trials excluded patients with nccRCC, which constitute about 30% of metastatic RCC cases.
To provide a piece of real-life evidence on the use of pazopanib in this patient subgroup.
The present study is a multicenter retrospective observational analysis aiming to assess the activity, efficacy, and safety of pazopanib as first-line therapy for advanced nccRCC patients treated in a real-life setting.
Overall, 48 patients were included. At the median follow-up of 40.6 mo, the objective response rate was 27.1%, the disease control rate was 83.3%, and the median progression-free survival and overall survival were 12.3 (95% confidence interval [CI]: 3.6-20.9) and 27.7 (95%CI: 18.2-37.1) mo, respectively. Grade 3 adverse events occurred in 20% of patients, and no grade 4 or 5 toxicities were found.
Pazopanib should be considered as a good first-line option for metastatic RCC with variant histology.
World journal of clinical oncology. 2021 Nov 24 [Epub]
Sebastiano Buti, Melissa Bersanelli, Francesco Massari, Ugo De Giorgi, Orazio Caffo, Gaetano Aurilio, Umberto Basso, Giacomo Carteni, Claudia Caserta, Luca Galli, Francesco Boccardo, Giuseppe Procopio, Gaetano Facchini, Giuseppe Fornarini, Alfredo Berruti, Elena Fea, Emanuele Naglieri, Fausto Petrelli, Roberto Iacovelli, Camillo Porta, Alessandra Mosca
Medical Oncology Unit, University Hospital of Parma, Parma 43126, Italy., Division of Oncology, Policlinico Sant'Orsola-Malpighi Hospital, Bologna 40138, Italy., Department of Oncology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola 47014, Italy., Department of Medical Oncology, Santa Chiara Hospital, Trento 38122, Italy., Department of Medical Oncology, Division of Urogenital and Head and Neck Tumours, European Institute of Oncology IRCCS, Milan 20141, Italy., Medical Oncology Unit 3, Istituto Oncologico Veneto IOV IRCCS, Castelfranco Veneto, Padova 31033, Italy., Division of Oncology, Azienda Ospedaliera di Rilievo Nazionale A. Cardarelli, Napoli 80131, Italy., Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni 05100, Italy., Oncology Unit 2, University Hospital of Pisa, Pisa 56126, Italy., Academic Unit of Medical Oncology, IRCCS San Martino Polyclinic Hospital, Genova 16132, Italy., Medical Oncology Genitourinary Section, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan 20133, Italy., Departmental Unit of Clinical and Experimental Uro-Andrologic Oncology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli 80131, Italy., Medical Oncology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Policlinico San Martino, Genova 16132, Italy., University of Brescia, ASST-Spedali Civili, Brescia, Brescia 25123, Italy., Medical Oncology Unit, S Croce and Carle Teaching Hospital, Cuneo 12100, Italy., Division of Medical Oncology, Istituto Tumori G Paolo II, IRCCS, Bari 70124, Italy., Medical Oncology Unit, ASST Bergamo Ovest, Treviglio, Bergamo 24047, Italy., Medical Oncology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome 00161, Italy., Division of Oncology, AOU Consorziale Policlinico di Bari, Bari 70124, Italy., Multidisciplinary Outpatient Oncology Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin 10060, Italy.